Literature DB >> 25587654

The JAK-STAT pathway: impact on human disease and therapeutic intervention.

John J O'Shea1, Daniella M Schwartz, Alejandro V Villarino, Massimo Gadina, Iain B McInnes, Arian Laurence.   

Abstract

The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related molecules. This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression. It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation. Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, especially cancer and immune-related conditions. The clinical relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.

Entities:  

Keywords:  autoimmunity; cancer; cytokine; immunodeficiency; kinase inhibitors

Mesh:

Substances:

Year:  2015        PMID: 25587654      PMCID: PMC5634336          DOI: 10.1146/annurev-med-051113-024537

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  74 in total

Review 1.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

2.  Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).

Authors:  Katja Butterbach; Lars Beckmann; Silvia de Sanjosé; Yolanda Benavente; Nikolaus Becker; Lenka Foretova; Marc Maynadie; Pierluigi Cocco; Anthony Staines; Paolo Boffetta; Paul Brennan; Alexandra Nieters
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

4.  A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory.

Authors:  Andrea M Siegel; Jennifer Heimall; Alexandra F Freeman; Amy P Hsu; Erica Brittain; Jason M Brenchley; Daniel C Douek; Gary H Fahle; Jeffrey I Cohen; Steven M Holland; Joshua D Milner
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

5.  The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.

Authors:  Camilla Nielsen; Henrik S Birgens; Børge G Nordestgaard; Lasse Kjaer; Stig E Bojesen
Journal:  Haematologica       Date:  2010-12-15       Impact factor: 9.941

Review 6.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

7.  Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

Authors:  David Ellinghaus; Eva Ellinghaus; Rajan P Nair; Philip E Stuart; Tõnu Esko; Andres Metspalu; Sophie Debrus; John V Raelson; Trilokraj Tejasvi; Majid Belouchi; Sarah L West; Jonathan N Barker; Sulev Kõks; Külli Kingo; Tobias Balschun; Orazio Palmieri; Vito Annese; Christian Gieger; H Erich Wichmann; Michael Kabesch; Richard C Trembath; Christopher G Mathew; Gonçalo R Abecasis; Stephan Weidinger; Susanna Nikolaus; Stefan Schreiber; James T Elder; Michael Weichenthal; Michael Nothnagel; Andre Franke
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

8.  Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody.

Authors:  Mi Young Koo; Jiyoung Park; Jung Mi Lim; Sei Yoon Joo; Seung-Pil Shin; Hyun Bo Shim; Junho Chung; Dongmin Kang; Hyun Ae Woo; Sue Goo Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

9.  Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Authors:  S R Chan; C G Rickert; W Vermi; K C F Sheehan; C Arthur; J A Allen; J M White; J Archambault; S Lonardi; T M McDevitt; D Bhattacharya; M V Lorenzi; D C Allred; R D Schreiber
Journal:  Cell Death Differ       Date:  2013-09-13       Impact factor: 15.828

10.  A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Authors:  W C Ports; S Khan; S Lan; M Lamba; C Bolduc; R Bissonnette; K Papp
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302

View more
  378 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 2.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 3.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

4.  JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.

Authors:  Jianling Tao; Laura Mariani; Sean Eddy; Holden Maecker; Neeraja Kambham; Kshama Mehta; John Hartman; Weiqi Wang; Matthias Kretzler; Richard A Lafayette
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-30       Impact factor: 8.237

Review 5.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

6.  Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model.

Authors:  Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

7.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

8.  MicroRNA-let-7e regulates the progression and development of allergic rhinitis by targeting suppressor of cytokine signaling 4 and activating Janus kinase 1/signal transducer and activator of transcription 3 pathway.

Authors:  Lihua Li; Shaorong Zhang; Xunshuo Jiang; Yuehui Liu; Ke Liu; Chunping Yang
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

10.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.